Recordati Industria Chimica e Farmaceutica SpA (REC.MI) Stock Price

Recordati Industria Chimica e Farmaceutica SpA Price

Borsa Italiana·CLOSED
52.80
​
Market closed

Revenue has compounded at 8.3% per year over the past 19 years to 2.62 B EUR. Earnings per share have grown at 9.9% per year over the last 19 years. Recordati Industria Chimica e Farmaceutica SpA's net margin stands at 16.9%, down from 24.4% several years earlier. Recordati Industria Chimica e Farmaceutica SpA currently offers a dividend yield of about 2.46%. The payout ratio is around 61% of earnings. The dividend has grown at 12.6% per year over the past 19 years. Analysts set a median price target of 58.65 EUR, implying 11.1% above the current price. Of 15 analysts, 8 rate the stock a buy — an overall Buy consensus.

Recordati Industria Chimica e Farmaceutica SpA stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recordati Industria Chimica e Farmaceutica SpA business model & stock analysis

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas.

Frequently asked questions about Recordati Industria Chimica e Farmaceutica SpA

Recordati Industria Chimica e Farmaceutica SpA operates as a leading international pharmaceutical company, specializing in research, development, manufacturing, and marketing of innovative and niche pharmaceutical products. The company's business model revolves around identifying unmet medical needs and developing targeted therapies. Recordati focuses on niche therapeutic areas such as rare diseases, genitourinary disorders, and cardiovascular diseases. By leveraging its global presence and extensive sales network, Recordati distributes its products to over 130 countries, ensuring widespread availability and patient access to its treatments. Through its commitment to innovation, quality, and patient care, Recordati Industria Chimica e Farmaceutica SpA continues to excel in the pharmaceutical industry.

Recordati Industria Chimica e Farmaceutica SpA is primarily active in the pharmaceutical industry. With a focus on research, development, manufacturing, and marketing of pharmaceutical products, Recordati is a leading player in the global healthcare sector. The company specializes in prescription drugs, with a portfolio that spans multiple therapeutic areas such as cardiovascular, central nervous system, urological, and rare diseases. Recordati's commitment to scientific innovation and patient care drives its success in delivering high-quality pharmaceutical solutions worldwide. As a reputable player in the pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA continues to contribute to advancements in healthcare and improve the quality of life for patients around the globe.

The main competitors of Recordati Industria Chimica e Farmaceutica SpA in the market include large pharmaceutical companies such as Novartis, Pfizer, and Sanofi. These companies operate in similar therapeutic areas and have significant market presence globally. However, Recordati distinguishes itself through its focus on niche markets, its expertise in rare diseases, and its strong distribution network. By maintaining a diversified product portfolio and continuously innovating, Recordati remains competitive in a dynamic pharmaceutical industry. Serving as a leading pharmaceutical company, Recordati Industria Chimica e Farmaceutica SpA faces competition from well-established players in the market.

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company with a rich history and extensive background. Established in 1926, Recordati has become a global leader in the pharmaceutical industry. The company specializes in the development, manufacturing, and marketing of innovative drugs and medical treatments. With a focus on research-driven solutions, Recordati has built a strong reputation for providing high-quality products that improve the health and well-being of patients worldwide. Over the years, they have expanded their presence across various therapeutic areas, including cardiovascular, urological, and rare diseases. As an esteemed pharmaceutical entity, Recordati Industria Chimica e Farmaceutica SpA continues to contribute significantly to the advancement of healthcare globally.

Recordati Industria Chimica e Farmaceutica SpA has achieved several significant milestones throughout its history. Founded in 1926, the company has established itself as a leading player in the pharmaceutical industry. Some of the notable achievements include successfully developing and launching innovative drugs, expanding its global presence through strategic partnerships and acquisitions, and consistently delivering strong financial performance. Recordati has also received numerous awards and recognitions for its contributions to the healthcare sector. With a strong focus on research and development, the company continues to innovate and create value for its stakeholders.

Recordati Industria Chimica e Farmaceutica SpA is primarily present in various countries and regions worldwide. The company has a strong presence in Italy, which serves as its headquarters. Additionally, Recordati has established operations and subsidiaries in several countries across Europe, including Spain, France, Germany, and the United Kingdom. Outside of Europe, the company has a significant presence in the United States, Canada, and Mexico, making it an important player in the North American pharmaceutical market. With its extensive global reach, Recordati Industria Chimica e Farmaceutica SpA is continuously expanding its presence and market share in the pharmaceutical industry.

Recordati Industria Chimica e Farmaceutica SpA represents values of excellence, innovation, and commitment to patient care in the pharmaceutical industry. As a leading global healthcare company, Recordati focuses on researching, developing, and marketing high-quality pharmaceuticals and treatments. With a strong dedication to scientific research, the company strives to improve patients' lives by providing effective and safe medications. Recordati's corporate philosophy emphasizes ethical conduct, transparency, and long-term relationships with healthcare professionals and patients. By maintaining a customer-centric approach, the company has built a reputation for delivering trusted and reliable products. Through its continuous pursuit of advancements and patient-focused values, Recordati Industria Chimica e Farmaceutica SpA remains a key player in the pharmaceutical sector.

Analysts currently set an average price target of 59.52 EUR for the Recordati Industria Chimica e Farmaceutica SpA stock (median: 58.65 EUR), implying +12.7 % versus the latest price. The consensus is based on 15 analyst ratings.

15 analysts currently rate the Recordati Industria Chimica e Farmaceutica SpA stock: 9 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Recordati Industria Chimica e Farmaceutica SpA to generate revenue of 2.80 B EUR and earnings per share of 2.45 EUR.

The Recordati Industria Chimica e Farmaceutica SpA share (REC.MI) is listed on 9 stock exchanges, including: London (0KBS.L), Frankfurt (RER1.F), München (RER1.MU), Düsseldorf (RER1.DU), Wien (REC.VI), Mailand (REC.MI).

The Recordati Industria Chimica e Farmaceutica SpA is a leading company in the pharmaceutical industry. Its goal is to provide innovative medications and treatment methods to help people with specific conditions. The business model of Recordati includes three main focuses: research and development, production, and marketing. In the research and development field, the company continuously works on developing new active ingredients and therapies to improve people's quality of life. Recordati's product range includes a variety of medications in different categories such as cardiology, urology, dermatology, and pain management. Some of the company's well-known products are Carbaglu, Cardiren, Ornilox, and Cystadrops. In terms of production, Recordati has a state-of-the-art infrastructure to ensure that all products are manufactured according to the highest quality standards. The company utilizes a combination of internal and external production facilities to maximize efficiency and flexibility. Recordati also has a wide distribution network to sell its products worldwide. The company operates in more than 100 countries and collaborates closely with various partners to ensure that patients around the world have access to high-quality medications. As part of its business strategy, Recordati has conducted various acquisitions and acquisitions to expand its market position and diversify its offerings. For example, the company recently acquired Tonipharm and Rottapharm Spa. Overall, Recordati has a strong and stable business strategy focused on long-term growth and value creation for all stakeholders. The company is expected to continue improving its production technologies and distribution systems and develop more innovative products to maintain a leading position in the pharmaceutical market.

The expected revenue of Recordati Industria Chimica e Farmaceutica SpA is 2.80 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Recordati Industria Chimica e Farmaceutica SpA is 511.80 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Recordati Industria Chimica e Farmaceutica SpA is currently 21.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Recordati Industria Chimica e Farmaceutica SpA stock.

The price-to-sales ratio (P/S) of Recordati Industria Chimica e Farmaceutica SpA is currently 3.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Recordati Industria Chimica e Farmaceutica SpA stock.

The Eulerpool Quality Score for Recordati Industria Chimica e Farmaceutica SpA is 9/10.

The ISIN of Recordati Industria Chimica e Farmaceutica SpA is IT0003828271. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Recordati Industria Chimica e Farmaceutica SpA is A0EABR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Recordati Industria Chimica e Farmaceutica SpA is REC.MI. The ticker symbol is used to trade Recordati Industria Chimica e Farmaceutica SpA shares on the stock exchange.

Fair ValueTerminal
53.86 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
605,686.56 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
EUR
Initial public offering
Jan 1, 1984
ISIN
IT0003828271
Cusip
T78458139
Sedol
B07DRZ5
Market capitalization
11.04 B EURLarge Cap
52-Week Range
PEG
1.36
P/E ratio
P/Ee 2026
21.57
P/Ee 2027
13.94
P/Ee 2028
12.72
P/Ee 2029
10.00
P/Ee 2030
9.31
P/S
P/Se
3.95
EV/EBIT
18.17
P/B Ratio
5.75
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
10.11 %
Dividend
Dividend yield
2.46 %
Est. Dividend Yield
2.69 %
Payout Ratio
61.29 %
Dividend growth Ø5Y
3.78 %
Dividend payments per year
2
Dividend paid since
36 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
26.00 %
Last updated Nov 20, 2026, 1:12 AM

Recordati Industria Chimica e Farmaceutica SpA Ticker

DÜSSELDORF · RER1.DUEURONEXT · REC.MIFRANKFURT · RER1.FLONDON · 0KBS.LMILAN · REC.MIMILAN · REC.MIMUNICH · RER1.MUOTC · RCDTFVIENNA · REC.VI

Recordati Industria Chimica e Farmaceutica SpA FIGI

REC:IM · BBG000BC7PF1REC:IC · BBG000BC7PV3REC:IF · BBG000BC7Q32RER1:GR · BBG000BTJPW2RER1:GF · BBG000BTJQ96RER1:GD · BBG000BTJQH7RER1:GS · BBG000BTJRN8RER1:GM · BBG000BTJSH3RER1:GB · BBG000BTJSY4RER1:GI · BBG000BTJTQ1RCDTF:US · BBG000BW0RW1RCDTF:UV · BBG000BW0YV7

All fundamentals and in-depth analysis of Recordati Industria Chimica e Farmaceutica SpA

Our stock analysis for Recordati Industria Chimica e Farmaceutica SpA stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recordati Industria Chimica e Farmaceutica SpA. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.